# Promoting Interoperability – The Illinois Prescription Monitoring Program









#### INTRODUCTION

- ILHITREC and CHITREC, in collaboration with the Department of Human Services, will discuss the Illinois Prescription Monitoring Program for public health reporting under the Medicaid Promoting Interoperability Program (formerly "Meaningful Use"). Sam Ross, CHITREC, will be the primary speaker in collaboration with Brenda Simms, ILHITREC, to explain requirements of the specialized registry measure.
- Stan Murzynski, IT and Edward Dowllar, MU Coordinators from ILPMP will present information about integrating your EHR to use the service for querying patient prescription history. The Illinois Prescription Monitoring Program (PMP) is an electronic tool that collects information on controlled substance prescriptions, schedules II, III, IV and V. This data is reported on a weekly basis by retail pharmacies dispensing in Illinois.

#### DISCLAIMER

- The target audience of this presentation is Eligible Providers, but some references may be made related to Eligible Hospitals.
- This webinar is based on official guidance provided by the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator (ONC), experiences from CHITREC, ILHITREC, and The Illinois Prescription Monitoring Program (ILPMP),
- This presentation was prepared as a tool to assist providers enrolled in the Promoting Interoperability Program administered by CMS. The tools presented today, are based on specific guidelines available at the time of the Webinar. The ultimate responsibility for compliance, submission and response to any remittance from CMS rests with the provider. CMS policy changes frequently. It is highly recommended that providers and their designee review rules and regulations frequently.

#### Agenda

- ILPMP Background
- ILPMP as a Specialized Registry for EHR Incentive Program
- Active Engagement with ILPMP
- Additional Info
- Q&A

#### Presenter Goals

At the end of this presentation you should be able to:

- Recognize the purpose and benefits of the ILPMP
- Know how ILPMP fits into the EHR Incentive Program
- Understand requirements of engaging with ILPMP for Promoting Interoperability (formerly "Meaningful Use") public health reporting

### **ILPMP Background**

### Prescription Drug Monitoring Programs

- Track eRx and dispensing data from pharmacies and providers
- Utilized by 49 states, DC + Guam to reduce drug abuse (schedules II-V)
- Access to PDMP may be available to providers, pharmacists, law enforcement, licensing/regulatory boards, Medicaid, coroners, research

### Illinois Prescription Monitoring Program

- Goal: assist prescribers and dispensers in effective treatment
- Voluntary and free, 24/7 access, available for mobile devices
- View prescriptions dispensed under DEA number
- Includes brief intervention form and link to treatment centers
- Supports integration with EHR, which is required for the EHR Incentive Program (not enough to use ILPMP website)

#### Illinois Public Act 100-0564

- Beginning 1/1/18, prescribers of controlled substances must be registered with ILPMP
- Must document attempt to query patient information from ILPMP before prescribing controlled substance
- Requires EHR connectivity with the PDMP by 2021 (Sec. 316, Line 22)

## Specialized Registries for the EHR Incentive Program

#### Objective 10: Public Health Reporting

- Medicaid Promoting Interoperability (formerly "Meaningful Use") Objective 10 requires public health reporting
- Objective 10:
  - "The EP is in *active engagement* with a public health agency to submit electronic public health data from CEHRT except where prohibited and in accordance with applicable law and practice."
  - Measure 1: Immunization Registry
  - Measure 2: Syndromic Surveillance
  - Measure 3: Specialized Registry ILPMP falls under this measure
- Stage 2 in 2018 requires two measures (may report on measure 3 twice)

## Objective 10, Measure 3: Specialized Registry

- To meet the measure, the EP must attest YES to being in *active engagement* to submit data to a specialized registry
- Exclusions: Any EP meeting at least one of the following criteria may be excluded from the specialized registry reporting measure if the EP-
  - Does not diagnose or treat any disease or condition associated with or collection of relevant data that is required by a specialized registry in their jurisdiction during the EHR Reporting Period
  - Operates in a jurisdiction for which no specialized registry is capable of accepting electronic transactions
  - Operates in a jurisdiction where no specialized registry for which the EP is eligible has declared readiness to receive electronic transactions
- No Exclusion for Measure 3 in Illinois means you <u>must</u> meet active engagement with a specialized registry unless you are actively engaged with both immunization <u>AND</u> syndromic

#### **Active Engagement: Option 1**

- Completed Registration to Submit Data:
  - The EP registered to submit data with the PHA within 60 days after the start of the EHR reporting period
  - EP is awaiting an invitation from the PHA or CDR to begin testing and validation
- Option 1 is enough to meet the measure for 2018 only

#### Active Engagement: Option 2

- Testing and Validation:
  - The EP is in the process of testing and validation of the electronic submission of data
  - Providers must respond to requests from the PHA or, where applicable, the CDR within 30 days
  - Failure to respond **twice** within an EHR reporting period would result in the provider not meeting the measure
- Option 2 is enough to meet the measure for 2018 only

#### **Active Engagement: Option 3**

#### • Production:

• The EP has completed testing and validation of the electronic submission and is electronically submitting production data to the PHA or CDR.

#### Production data

- Refers to data generated through clinical processes involving patient care
- It is used to distinguish between data and "test data" which may be submitted for the purposes of enrolling in and testing electronic data transfers.
- Option 3 meets measure for 2018 and future years if remaining in production

## Active Engagement with ILPMP

#### Registration of Intent

- Register at MURS system (<a href="https://murs.Illinois.gov">https://murs.Illinois.gov</a>)
- Select "Yes" to ILPMP:



• Identify technical contact (receives follow-up with details on connecting EHR):

Technical (IT) Contact Person				
* Name				
* Position				

#### Registration Confirmation

• Immediately receive email from <a href="mailto:dph.murs.contact@Illinois.gov">dph.murs.contact@Illinois.gov</a>

• Maintain for audit records

To: Public Chicago Ave.
Chicago, 60622

From : Illinois Department of Public Health

Date: 11/8/2017

Subject : Meaningful Use Stage 2 Registration of Intent Confirmation

Re:1194756908

This memo confirms your registration for Meaningful Use Stage 2


IPMP (Illinois Prescription Monitoring Program). For questions: DHS.PMP@Illinois.gov

This registration places you in the Active Engagement Status: Option 1 Completed registration to Submit Data. Additional information about satisfying MU Modified Stage 2 and Stage 3, Per, 80 16742 is here: (https://www.federalregister.gov/documents/2015/10/16/2015-25595/medicare-and-medicaid-programs-electronic-health-record-incentive-program-stage-3-and-modifications)

#### Pre Connection/Testing

- Receive invitation from
  - DHS.PMP@Illinois.gov
  - <u>Edward.dowllar@Illinois.gov</u>
  - <u>Craig.berberet@Illinois.gov</u>
  - <u>Stanley.Murzynski@Illinois.gov</u>
- A meeting is set up with Logicoy to discuss possible connection solutions
  - Restful based NCPDP
  - SOAP based PMIX
  - FHIR
- Partner with CEHRT vendor to establish interfacing with Logicoy
  - Logicoy can provide assistances with this including premade EHR interfaces in some instances
  - CEHRT vendor contact can participate as well
- Send test data
- Go Live!

#### **Production**



#### **Production**

#### Illinois Board of Pharmacy

320 W. Washington, 3<sup>rd</sup> Floor Springfield, IL 62786-0001 Phone (217) 782-8556 Fax (217) 782-7645 URL: http://www.idfpr.com

2013-01-22

line1

The Illinois Prescription Monitoring Program has identified:

bilbo baggins (DOB: 1959-12-26)

as one of your patients. This person appears to be obtaining controlled substance prescriptions of the same or similar nature from multiple practitioners and multiple pharmacies. We have developed no conclusions or judgments on the basis of this information; however, in the event this observation should concern you, we suggest you query this person's prescription history at the IL-PDMP website if you require additional or updated information.

Following your review and assessment of the prescription data for this person, you should, as always, act according to your informed professional judgment.

We have provided this requested report in support of the program's mission to identify and inhibit the diversion of controlled substances in a manner that will not impede the appropriate utilization of these medications for legitimate medical purposes.


Sincerely,

Name TBD

Title TBD

DT Disp	Qty	Days	Drug Name	Dispenser	City	Prescriber
2012-11-26	30		HYDROCODONE BIT/ACETAMINOPHEN	CVS/PHARMACY #08632	DECATUR	LEE
2012-11-19	10		TESTOSTERONE CYPIONATE	CVS/PHARMACY #08632	DECATUR	YETURU
2012-11-24	20		HYDROCODONE BIT/ACETAMINOPHEN	CVS/PHARMACY #08632	DECATUR	REYES

#### Production



#### **Additional Info**


#### Confirmation of Active Engagement

- Request confirmation of active engagement status during Promoting Interoperability (formerly "Meaningful Use") reporting period
- Email <u>DHS.PMP@Illinois.gov</u> with:
  - Subject line: "Confirmation for Promoting Interoperability"
  - Body of email:
    - Your organization name and HL7 ID (starts with "777" or "888")
    - Your provider name(s)
    - Reporting period


#### eMIPP Attestation

- Report under MU-Public Health Measures tab
- Open Measure 3: Specialized Registry Reporting
- Select "No" to Specialty Registry Availability Verification unless you are claiming exclusions from all other public health measures
- Select "No" to Exclusion and "Yes" to Compliance
- Choose ILPMP under Registry Details
- Upload confirmation of active engagement into Upload Document

#### eMIPP Attestation



#### eMIPP Attestation



#### Stage 3 Requirement

- Phased out "specialized registry" measure; ILPMP will fall under Measure 4: Public Health Registry
- For Measure 4, a provider may count a specialized registry (such as prescription drug monitoring) if the provider achieved Active Engagement Option 3: Production in a prior year
- Must attest to *active engagement option 3* with ILPMP in 2018 (or earlier) in order to use it for Stage 3 public health reporting in 2019


#### Medicare QPP + MIPS

- Medicare MIPS has a "Promoting Interoperability" category
- MIPS "Promoting Interoperability" has an optional public health reporting measure
- Active engagement with ILPMP can earn MIPS bonus points

#### Web References

- PDMP Assist FAQ
- Illinois Prescription Drug Monitoring Program website
- Illinois Public Act 100-0564
- LogiCoy PDMP
- Demonstration of PDMP integration with AllScripts

#### Questions??



#### Contact Information



Email: <a href="mailto:info@chitrec.org">info@chitrec.org</a>
Phone: 312 503-2986



Email: <u>info@ilhitrec.org</u> Phone: 815-753-5900



Illinois Prescription Monitoring Program

Prescription Monitoring 401 North Fourth Street Springfield, IL 62702

Fax: (217) 557-7975 Phone: (217) 524-1311